 Vincristine
"Vincristine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antitumor alkaloid isolated from Vinca Rosea. (Merck, 11th ed.)
| Descriptor ID |
D014750
|
| MeSH Number(s) |
D03.132.436.681.827.817 D03.438.473.402.681.827.817
|
| Concept/Terms |
Citomid- Citomid
- Lemery Brand of Vincristine Sulfate
Oncovin- Oncovin
- Vincristin Liquid, Lilly
- Oncovine
- EG Labo Brand of Vincristine Sulfate
- Lilly Brand of Vincristine Sulfate
Onkocristin- Onkocristin
- Onkoworks Brand of Vincristine Sulfate
Vintec- Vintec
- Columbia Brand of Vincristine Sulfate
Vincasar PFS- Vincasar PFS
- PFS, Vincasar
- Teva Brand of Vincristine Sulfate
Vincrisul- Vincrisul
- Irisfarma Brand of Vincristine Sulfate
cellcristin- cellcristin
- cell pharm Brand of Vincristine Sulfate
Vincasar- Vincasar
- Pfizer Brand of Vincristine Sulfate
- Farmistin
|
Below are MeSH descriptors whose meaning is more general than "Vincristine".
Below are MeSH descriptors whose meaning is more specific than "Vincristine".
This graph shows the total number of publications written about "Vincristine" by people in UAMS Profiles by year, and whether "Vincristine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 0 | 1 | | 2021 | 0 | 2 | 2 | | 2020 | 0 | 4 | 4 | | 2019 | 0 | 2 | 2 | | 2018 | 0 | 1 | 1 | | 2016 | 1 | 0 | 1 | | 2015 | 0 | 4 | 4 | | 2014 | 0 | 3 | 3 | | 2013 | 1 | 3 | 4 | | 2012 | 1 | 3 | 4 | | 2011 | 0 | 2 | 2 | | 2010 | 1 | 3 | 4 | | 2009 | 1 | 1 | 2 | | 2008 | 0 | 3 | 3 | | 2007 | 0 | 4 | 4 | | 2006 | 0 | 2 | 2 | | 2005 | 0 | 1 | 1 | | 2003 | 2 | 2 | 4 | | 2002 | 0 | 4 | 4 | | 2001 | 1 | 2 | 3 | | 2000 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Vincristine" by people in Profiles over the past ten years.
-
Delgado M, Rainwater RR, Heflin B, Urbaniak A, Butler K, Davidson M, Protacio RM, Baldini G, Edwards A, Reed MR, Raney KD, Chambers TC. Primary acute lymphoblastic leukemia cells are susceptible to microtubule depolymerization in G1 and M phases through distinct cell death pathways. J Biol Chem. 2022 06; 298(6):101939.
-
Mohan M, Meek JC, Meek ME, Broadwater R, Alapat D, van Rhee F. Combinatorial treatment for unresectable unicentric Castleman disease. Eur J Haematol. 2021 Oct; 107(4):484-488.
-
Sparano JA, Lee JY, Kaplan LD, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. Haematologica. 2021 03 01; 106(3):730-735.
-
Urbaniak A, Piña-Oviedo S, Yuan Y, Huczynski A, Chambers TC. Limitations of an ex vivo breast cancer model for studying the mechanism of action of the anticancer drug paclitaxel. Eur J Pharmacol. 2021 Jan 15; 891:173780.
-
Ramos JC, Sparano JA, Chadburn A, Reid EG, Ambinder RF, Siegel ER, Moore PC, Rubinstein PG, Durand CM, Cesarman E, Aboulafia D, Baiocchi R, Ratner L, Kaplan L, Capoferri AA, Lee JY, Mitsuyasu R, Noy A. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood. 2020 09 10; 136(11):1284-1297.
-
Bradbury CA, Craig Z, Cook G, Pawlyn C, Cairns DA, Hockaday A, Paterson A, Jenner MW, Jones JR, Drayson MT, Owen RG, Kaiser MF, Gregory WM, Davies FE, Child JA, Morgan GJ, Jackson GH. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood. 2020 08 27; 136(9):1091-1104.
-
Duong VH, Begna KH, Kashanian S, Sweet K, Wang ES, Caddell R, Shafer DA, Singh ZN, Baer MR, Al-Kali A. Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. Ann Hematol. 2020 Sep; 99(9):2119-2124.
-
Bukhari A, El Chaer F, Koka R, Singh Z, Hutnick E, Ruehle K, Lee ST, Kocoglu MH, Shanholtz C, Badros A, Hardy N, Yared J, Rapoport AP, Dahiya S. Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss. Am J Hematol. 2019 10; 94(10):E273-E275.
-
Huang YH, Zhou DB, Han B, Li T, Wang SJ. Successful treatment of an adult with Kasabach-Merritt syndrome using thalidomide, vincristine, and prednisone. J Int Med Res. 2019 Apr; 47(4):1810-1814.
-
Delgado M, Chambers TC. Microtubules play an essential role in the survival of primary acute lymphoblastic leukemia cells advancing through G1 phase. Cell Cycle. 2018; 17(14):1784-1796.
-
Kothari A, Hittelman WN, Chambers TC. Cell Cycle-Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells. Cancer Res. 2016 06 15; 76(12):3553-61.
-
Epeldegui M, Lee JY, Martínez AC, Widney DP, Magpantay LI, Regidor D, Mitsuyasu R, Sparano JA, Ambinder RF, Martínez-Maza O. Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). Clin Cancer Res. 2016 Jan 15; 22(2):328-36.
-
Li Z, Li F, Yi S, Gu Z, Yu Z, Xu Y, Feng X, Liu W, Zou D, Qi J, Zhan F, Qiu L. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. BMC Cancer. 2015 Jul 29; 15:555.
-
Abdallah AO, Bansal M, Kemp SA, Schichman SA, Xiang Z. A unique presentation of unilateral pleural effusion in a patient with a high-grade plasma cell neoplasm. Leuk Lymphoma. 2015; 56(10):2989-91.
-
Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015 Jul 09; 126(2):160-6.
-
Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol. 2014 Nov; 167(3):394-401.
-
Lapa C, Knott M, Rasche L, Herrmann K, Buck AK, Rosenwald A. Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms. Eur J Haematol. 2014 Dec; 93(6):545-6.
-
Cao XX, Li J, Zhang W, Duan MH, Shen T, Zhou DB. Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse. Ann Hematol. 2014 Jun; 93(6):1001-5.
-
Kaplan LD, Deitcher SR, Silverman JA, Morgan G. Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):37-42.
-
Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Oriol A, Navarro JT, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013 Nov 07; 122(19):3251-62.
-
Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, Harrison L, Sanger W, Geyer MB, Giulino-Roth L, Cairo MS. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. Br J Haematol. 2013 Sep; 162(5):678-83.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|